Table 2.
Pharmacokinetic parameters for DMT based on non–compartmental analyses [geometric mean (95% CI), range].
| Low infusion (0.6 mg/min) | High infusion (1.0 mg/min) | Low bolus (15 mg) + low infusion (0.6 mg/min) | High bolus (2 5 mg) + high infusion (1.0 mg/min) | |
|---|---|---|---|---|
| Cmax (ng/ml) | 24 (21–28) | 39 (33–45) | 29 (26–33)a | 61 (51–73)a |
| 11–48 | 15–83 | 14–56 | 11–107 | |
| Tmax (min) | 72 (67–78) | 73 (64–83) | 2.5 (2.1–2.9)a | 2.9 (2.4–3.6)a |
| 40–90 | 15–90 | 2–5 | 2–10 | |
| t1/2α (min) | 5.3 (4.5–6.1) | 5.3 (4.7–5.9) | 5.0 (4.4–5.6) | 5.8 (5.1–6.5) |
| 3.0–15 | 3.2–10.0 | 2.9–11 | 2.8–11 | |
| t1/2β (min) | 15 (13–16) | 15 (14–16) | 14 (13–16) | 16 (14–17) |
| 7.8–29 | 10–22 | 7.5–23 | 10–22 | |
| CL (L/min) | 39 (34–46) | 39 (33–46) | 36 (32–42) | 36 (32–40) |
| 16–97 | 16–91 | 21–82 | 22–61 | |
| Vz (L) | 820 (671–1004) | 831 (683–1012) | 746 (639–871) | 799 (693–922) |
| 287–2765 | 284–2133 | 388–1945 | 379–1752 | |
| AUC∞ (ngamin/ml) | 1374 (1174–1607) | 2303 (1966–2697) | 1902 (1653–2189) | 3220 (2889–3588) |
| 554–3374 | 987–5764 | 839–3212 | 1883–5247 |
AUC area under the plasma concentration-time curve, AUC∞ AUC from time zero to infinity, CL apparent total clearance, Cmax maximum observed plasma concentration, t1/2α early elimination plasma half-life, t1/2β late elimination plasma half-life, Tmax time to reach Cmax, 95%CI 95% confidence interval, Vz apparent volume of distribution, n = 27.
aIn the DMT bolus conditions, Cmax and Tmax values were calculated considering only plasma concentrations within the first 15 min after the bolus application.